Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, January 12 '25)

Image
By G.M.

 


    BMJ

  1. KAST KA, Sidelnik SA, Nejad SH, Suzuki J, et al
    Management of alcohol withdrawal syndromes in general hospital settings.
    BMJ. 2025;388:e080461.
    PubMed         Abstract available


    Clin Infect Dis

  2. XIANG W, Steinbeis F, Dhindsa K, Kurth F, et al
    Predicting the risk of intensive care unit admission in patients with COVID-19 presenting in the emergency room: Development and evaluation of the CROSS score.
    Clin Infect Dis. 2025 Jan 10:ciaf006. doi: 10.1093.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  3. NAKASHITA M, Kurosawa K, Fukusumi M, Irie F, et al
    Improving the ability of psychiatric hospitals to respond to infectious disease outbreaks: lessons learned from the COVID-19 outbreak response in Ibaraki Prefecture, Japan.
    Infect Control Hosp Epidemiol. 2025 Jan 8:1-2. doi: 10.1017/ice.2024.
    PubMed        

  4. VAN REST A, Clarke A, Gounder P, Nie PK, et al
    COVID-19 outbreaks in nursing homes in Los Angeles County, March 2020-April 2022.
    Infect Control Hosp Epidemiol. 2025 Jan 7:1-7. doi: 10.1017/ice.2024.
    PubMed         Abstract available


    J Infect

  5. ONG DS, Harris M, Hart JD, Russell FM, et al
    Lack of correlation between school reopening and trends in adult COVID-19 hospitalisations and death rates during the Delta and early Omicron periods: an ecological analysis of five countries.
    J Infect. 2025 Jan 6:106390. doi: 10.1016/j.jinf.2024.106390.
    PubMed         Abstract available

  6. JORDA A, Prager M, Pracher L, Haselwanter P, et al
    Immunogenicity, Safety, and Reactogenicity of Concomitant Administration of the Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=60 Years: A Randomised, Double-blind, Placebo-contro
    J Infect. 2025 Jan 3:106405. doi: 10.1016/j.jinf.2024.106405.
    PubMed         Abstract available


    J Med Virol

  7. ZHANG S, Kong X, Zhen Q, Wei Y, et al
    Dynamic Changes and Trends of SARS-CoV-2 Antibodies Induced by Infection and Vaccination Across Multiple Time Points.
    J Med Virol. 2025;97:e70161.
    PubMed         Abstract available

  8. KO C, Cheng CC, Mistretta D, Ambike S, et al
    SARS-CoV-2 Productively Infects Human Hepatocytes and Induces Cell Death.
    J Med Virol. 2025;97:e70156.
    PubMed         Abstract available


    J Virol

  9. GRIMES SL, Heaton BE, Anderson ML, Burke K, et al
    The coronavirus nsp14 exoribonuclease interface with the cofactor nsp10 is essential for efficient virus replication and enzymatic activity.
    J Virol. 2025 Jan 10:e0170824. doi: 10.1128/jvi.01708.
    PubMed         Abstract available

  10. ARORA P, Zhang L, Nehlmeier I, Kempf A, et al
    Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D.
    J Virol. 2025 Jan 10:e0123024. doi: 10.1128/jvi.01230.
    PubMed         Abstract available

  11. HU H, Leng C, Shu Y, Peng L, et al
    Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2.
    J Virol. 2025 Jan 7:e0130724. doi: 10.1128/jvi.01307.
    PubMed         Abstract available

  12. GUNAWARDENE CD, Wong L-YR
    Betacoronavirus internal protein: role in immune evasion and viral pathogenesis.
    J Virol. 2025 Jan 6:e0135324. doi: 10.1128/jvi.01353.
    PubMed         Abstract available


    Life Sci

  13. CHOPRA A, Franko N, Chow EJ
    Navigating neurologic post-COVID-19 conditions in adults: Management strategies for cognitive dysfunction, headaches and neuropathies.
    Life Sci. 2025;362:123374.
    PubMed         Abstract available


    Zhonghua Jie He He Hu Xi Za Zhi

  14. SONG LC, Xie LX
    [Clinical update in critical care of pulmonary medicine 2024].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:84-89.
    PubMed         Abstract available

  15. LI SN, Ni WT, Li R, Chen YW, et al
    [Clinical characteristics of immunocompromised patients infected with COVID-19].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:35-42.
    PubMed         Abstract available


  16. [Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly (2024 Edition)].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:18-34.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »